DT&CRO CO., Ltd. (KOSDAQ:383930)

Market Cap	42.89B -49.8%
Revenue (ttm)	47.75B +32.7%
Net Income	-2.78B
EPS	-217.00
Shares Out	12.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,148
Average Volume	288,058
Open	3,225.00
Previous Close	3,255.00
Day's Range	3,150.00 - 3,410.00
52-Week Range	2,250.00 - 9,370.00
Beta	1.50
RSI	65.56
Earnings Date	n/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.

• Industry: Commercial Physical and Biological Research
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 383930

Financial Performance

In 2025, DT&CRO CO.'s revenue was 47.75 billion, an increase of 32.74% compared to the previous year's 35.97 billion. Losses were -2.78 billion, 38.9% more than in 2024.